We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · August 20, 2020

Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Triple-Negative Breast Cancer

JAMA Oncology

 

Additional Info

JAMA Oncology
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial
JAMA Oncol 2020 Aug 13;[EPub Ahead of Print], KD Yu, FG Ye, M He, L Fan, D Ma, M Mo, J Wu, GY Liu, GH Di, XH Zeng, PQ He, KJ Wu, YF Hou, J Wang, C Wang, ZG Zhuang, CG Song, XY Lin, A Toss, F Ricci, ZZ Shen, ZM Shao

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading